Description

Basic Info.

Semaglutide is a long‑acting glucagon‑like peptide‑1 (GLP‑1) receptor agonist developed by Novo Nordisk, with 94% structural homology to human native GLP‑1, serving as a cornerstone in metabolic disease management. Mechanism of action: It enhances glucose‑dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, delivering glycemic control, weight reduction, and cardiovascular protection. Indications: Glycemic control in adults with type 2 diabetes; reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; long‑term weight management in adults with obesity or overweight plus at least one weight‑related comorbidity. Formulations: Once‑weekly injection (Ozempic), oral tablet (Rybelsus), and weight‑management dedicated formulation (Wegovy). Common adverse reactions: Mild‑to‑moderate gastrointestinal events including nausea, diarrhea, vomiting, constipation, and abdominal pain, mostly tolerable and transient. Contraindications: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy/lactation, and severe gastrointestinal diseases.

packing & Delivery

Product packaging

We have cooperated with experienced shipping forwarders for many years, they arrange the shipment. No matter by express, by air or by sea, we will track the course of the goods all the way, to make sure goods arrive at you on time and in good condition.

< Previous

BPC 157

Next >

Hyaluronic acid

Send A Message

We'd love to hear from you if you have any questions!

submit review submit review

Related Products

MOTS-c

BPC 10mg + TB 10mg

BPC 5mg + TB 5mg

10ml*